Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ofatumumab in adults with active rheumatoid arthritis receiving non-biologic DMARDs
2007-002945-18Phase 3Terminated
- Sponsor
- Genmab
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Ofatumumab arm with Placebo arm (2 arms). Primary endpoint: ACR20 response at 24 weeks. Started Aug 2007; status: terminated.
02
Drugs
ofatumumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-002945-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002945-18.